As per the report by Fortune Business Insights, the global normal saline for parenteral use market size is projected to reach USD 5.48 billion in 2030, at.
China Dexmedetomidine Market Report 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
China Dexmedetomidine Market Report 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Investigation Report on China's Dexmedetomidine Markets, 2016-2020 & 2021-2025 – ResearchAndMarkets.com financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Share this article Share this article ResearchAndMarkets.com s offering. In 2021-2025, the Chinese ambroxol market will gradually recover. It is estimated that the sales of ambroxol in China will reach CNY924 million in 2025, and the CAGR will reach 10% in 2021-2025. Due to the outbreak of COVID-19 in 2020, the ability of Chinese hospitals to receive patients has declined. The decrease in the number of people seeking medical care makes China s sales and sales of ambroxol show a downward trend in 2020. The sales of amboxol in China dropped by 34% in 2020, compared to 2019. According to the analyst, the incidence and case fatality rate of respiratory diseases in China are high in recent years. Following cardiovascular and cerebrovascular diseases and cancers, respiratory diseases rank third among the chronic diseases that cause deaths in China.
Share this article Share this article ResearchAndMarkets.com s offering. In 2021-2025, the Chinese ambroxol market will gradually recover. It is estimated that the sales of ambroxol in China will reach CNY924 million in 2025, and the CAGR will reach 10% in 2021-2025. Due to the outbreak of COVID-19 in 2020, the ability of Chinese hospitals to receive patients has declined. The decrease in the number of people seeking medical care makes China s sales and sales of ambroxol show a downward trend in 2020. The sales of amboxol in China dropped by 34% in 2020, compared to 2019. According to the analyst, the incidence and case fatality rate of respiratory diseases in China are high in recent years. Following cardiovascular and cerebrovascular diseases and cancers, respiratory diseases rank third among the chronic diseases that cause deaths in China.